hepatocellular carcinoma
Conditions
Interventions
One TACE for one HCC. administrated dose
d cm= Dx10 mg
Sponsors
Nara Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: unresectable HCC with contraindication of local ablation therapy confirmed histologically or clinically by diagnostic imaging; no extrahepatic metastasis; tumor size less than 10 cm and tumor located in one segmental area or three subsegmental areas; no lingering effects of previous therapy; Eastern Cooperative Oncology Group performance status of 0 to 2; Child-Pugh classification A or B; maintenance of adequate bone marrow, kidney, cardiac function, and meeting clinical laboratory test criteria; age more than 20 years; life expectancy more than 3 months; and provision of written informed consent.
Exclusion criteria
Exclusion criteria: obvious development of feeding artery from an extrahepatic artery (e.g., inferior phrenic artery, inferior adrenal artery, internal mammary artery) to tumor; previous pancreato-biliary surgery or endoscopic sphincteropapillotomy; serious complications other than chronic hepatitis or liver cirrhosis; a history of allergy to iodine-containing agents or contrast media; extrahepatic metastasis; concomitant malignancy; active clinically serious infections; advanced arteriovenous shunt or arterioportal shunt; pregnant or lactating women, or women of childbearing potential; and other serious medical conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year local disease-free survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| safety, time to progression and 2-year overall survival rate | — |
Countries
Japan
Contacts
Public ContactHideyuki Nishiofuku
Nara Medical University Radiology
Outcome results
None listed